Growth Metrics

Merck (MRK) Income from Non-Controlling Interests (2009 - 2026)

Merck (MRK) reported Income from Non-Controlling Interests of -$3.0 million for Q1 2026, down 150.0% year-over-year from $6.0 million in Q1 2025, and down 200.0% on a QoQ basis from -$1.0 million in Q4 2025.

Merck (MRK) has 18 years of Income from Non-Controlling Interests data on file, last reported at -$3.0 million in Q1 2026.

  • Quarterly Income from Non-Controlling Interests fell 150.0% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 105.88% YoY) and the FY2025 annual result came in at $9.0 million, down 43.75% from the prior year.
  • Income from Non-Controlling Interests eased to -$3.0 million in Q1 2026 per MRK's latest filing, from -$1.0 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $6.0 million in Q2 2024 and bottomed at -$3.0 million in Q1 2022.
  • The 5-year median for Income from Non-Controlling Interests is $3.5 million (2023), against an average of $2.6 million.
  • The widest annual swing landed in 2022, when Income from Non-Controlling Interests soared 400.0%; it then slumped 200.0% in 2025.
  • Tracing MRK's Income from Non-Controlling Interests over 5 years: stood at $1.0 million in 2022, then soared by 400.0% to $5.0 million in 2023, then plunged by 80.0% to $1.0 million in 2024, then tumbled by 200.0% to -$1.0 million in 2025, then tumbled by 200.0% to -$3.0 million in 2026.
  • Per Business Quant, the three latest MRK Income from Non-Controlling Interests figures stand at -$3.0 million (Q1 2026), -$1.0 million (Q4 2025), and $2.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 2.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -3.00 Mn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 8.00 Mn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 1.00 Mn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -3.00 Mn
Dec 31, 2025 -1.00 Mn
Sep 30, 2025 2.00 Mn
Jun 30, 2025 1.00 Mn
Mar 31, 2025 6.00 Mn
Dec 31, 2024 1.00 Mn
Sep 30, 2024 4.00 Mn
Jun 30, 2024 6.00 Mn
Mar 31, 2024 5.00 Mn
Sep 30, 2023 5.00 Mn
Jun 30, 2023 3.00 Mn
Mar 31, 2023 4.00 Mn
Dec 31, 2022 1.00 Mn
Sep 30, 2022 5.00 Mn
Jun 30, 2022 5.00 Mn
Mar 31, 2022 -3.00 Mn
Dec 31, 2021 4.00 Mn
Sep 30, 2021 4.00 Mn
Jun 30, 2021 1.00 Mn
Mar 31, 2021 4.00 Mn
Dec 31, 2020 3.00 Mn
Sep 30, 2020 2.00 Mn
Jun 30, 2020 4.00 Mn
Dec 31, 2019 -11.00 Mn
Sep 30, 2019 6.00 Mn
Jun 30, 2019 -26.00 Mn
Mar 31, 2019 -53.00 Mn
Dec 31, 2018 -49.00 Mn
Sep 30, 2018 8.00 Mn
Jun 30, 2018 9.00 Mn
Mar 31, 2018 5.00 Mn
Dec 31, 2017 8.00 Mn
Sep 30, 2017 5.00 Mn
Jun 30, 2017 5.00 Mn
Mar 31, 2017 5.00 Mn
Dec 31, 2016 8.00 Mn
Sep 30, 2016 4.00 Mn
Jun 30, 2016 4.00 Mn
Mar 31, 2016 5.00 Mn
Dec 31, 2015 5.00 Mn
Sep 30, 2015 5.00 Mn
Jun 30, 2015 1.00 Mn
Mar 31, 2015 5.00 Mn
Dec 31, 2014 11.00 Mn
Sep 30, 2014 -53.00 Mn
Jun 30, 2014 29.00 Mn
Mar 31, 2014 26.00 Mn
Dec 31, 2013 34.00 Mn
Sep 30, 2013 26.00 Mn
Jun 30, 2013 29.00 Mn
Mar 31, 2013 23.00 Mn
Dec 31, 2012 42.00 Mn
Sep 30, 2012 34.00 Mn
Jun 30, 2012 27.00 Mn
Mar 31, 2012 29.00 Mn
Dec 31, 2011 31.00 Mn
Sep 30, 2011 32.00 Mn
Jun 30, 2011 30.00 Mn
Mar 31, 2011 28.00 Mn
Dec 31, 2010 32.00 Mn
Sep 30, 2010 30.00 Mn
Jun 30, 2010 28.00 Mn
Mar 31, 2010 31.00 Mn
Dec 31, 2009 29.20 Mn
Sep 30, 2009 31.00 Mn
Jun 30, 2009 32.00 Mn
Mar 31, 2009 30.80 Mn